Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | GCK | P35557 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858054 | 1.00 | KCNH2 (0.53) | KCNH2GCKNPC1SMN1; SMN2RAB9A | |
| SCHEMBL1860567 | 0.89 | KCNH2 (0.69) | KCNH2GCKNPC1SMN1; SMN2RAB9A | |
| SCHEMBL1860566 | 0.89 | KCNH2 (0.69) | KCNH2GCKNPC1SMN1; SMN2RAB9A | |
| SCHEMBL1862395 | 0.87 | KCNH2 (0.49) | KCNH2GCKKCNQ2SLC6A3FFAR2 | |
| SCHEMBL1862392 | 0.87 | KCNH2 (0.49) | KCNH2GCKKCNQ2SLC6A3FFAR2 | |
| SCHEMBL1861801 | 0.86 | KCNH2 (0.48) | KCNH2GCKKCNQ2SLC6A3 | |
| SCHEMBL1861804 | 0.86 | KCNH2 (0.48) | KCNH2GCKKCNQ2SLC6A3 | |
| SCHEMBL1861975 | 0.85 | KCNH2 (0.47) | KCNH2GCKLMNAKCNQ2SLC6A3 | |
| SCHEMBL1861977 | 0.85 | KCNH2 (0.47) | KCNH2GCKLMNAKCNQ2SLC6A3 | |
| SCHEMBL1860656 | 0.85 | KCNH2 (0.51) | KCNH2GCKLMNAKCNQ2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| EP-2261216-A2 | Pyrazoles as glucokinase activators | F. Hoffmann-La Roche AG (CH) | 2010-12-15 | — | — | EP | disclosed |
| EP-2046755-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. Hoffmann-Roche AG (CH) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008012227-A2 | PYRAZOLES AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-01-31 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | KCNH2 2241/4885GCK 2/4885NPC1 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.